Genprex Inc Stock Price, News & Analysis

Genprex, Inc. (NASDAQ: GNPX) announced its participation in the Diamond Equity Research Emerging Growth Invitational, set for December 1, 2020, at 11:40 a.m. EST. Executive Vice President Michael Redman will present a company overview and engage in a Q&A session. The virtual event aims to showcase Genprex's advancements in gene therapies for cancer and diabetes. The company's leading drug candidate, REQORSA™, is in development for non-small cell lung cancer and has received Fast Track Designation from the FDA. More details can be found on Genprex's website.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will join a panel at the virtual Life Sciences Summit on November 17-18, 2020. The panel, titled “Show Me the Money: Preparing Your Company for Funding,” aims to guide emerging companies in securing funding. Key topics will include intellectual property strategy, due diligence, and investor relations. The Life Sciences Summit connects early-stage investors with innovative companies and academic professionals to advance clinical developments.

Genprex, Inc. (NASDAQ: GNPX) has appointed Dr. George K. Gittes to its Scientific Advisory Board. Dr. Gittes is recognized for his work on the company's diabetes gene therapy technology, which has the potential to provide a cure for diabetes, affecting over 30 million people in the U.S. This addition is expected to enhance Genprex’s strategy as it advances its diabetes clinical development program. Rodney Varner, President and CEO of Genprex, noted the importance of Dr. Gittes' expertise in driving the company's efforts to benefit patients with diabetes.

Genprex, Inc. (NASDAQ: GNPX) announced the launch of new branding for its upcoming oncology clinical trials combining its lead drug candidate, REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso® (osimertinib) and Merck’s Keytruda® (pembrolizumab) for non-small cell lung cancer (NSCLC). The trials, branded as 'Acclaim,' aim to provide hope for NSCLC patients. Acclaim-1 targets late-stage NSCLC with mutated EGFRs, while Acclaim-2 targets low expressors of PD-L1. The trials are expected to commence in the first half of 2021.

Genprex, Inc. (NASDAQ: GNPX) announced that the FDA has conditionally accepted the proprietary name REQORSA™ for its lead drug candidate targeting non-small cell lung cancer, previously known as GPX-001. This name approval is a critical step towards marketing the therapy and enhances the brand identity of Genprex. The REQORSA drug utilizes the ONCOPREX® nanoparticle delivery system and previously received Fast Track Designation from the FDA. Final approval of the name is contingent upon successful clinical trials and FDA product candidate approval.

Genprex, Inc. (GNPX) has promoted Eric Chapdelaine to Vice President of Manufacturing, reflecting the company’s progress in scaling its manufacturing operations. This comes as Genprex prepares for upcoming Phase I/II clinical trials of its lead candidate, GPX-001, in combination with AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLC). The company received FDA Fast Track Designation for GPX-001 in January 2020, aimed at improving treatment options for patients who have progressed on prior therapies.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present virtually at the Zooming with LD Micro event on October 14 at 11 a.m. ET. CEO Rodney Varner will lead the presentation followed by a Q&A session. Genprex focuses on developing technologies for cancer and diabetes patients, with its lead product candidate, GPX-001, aimed at treating non-small cell lung cancer (NSCLC). The FDA has granted GPX-001 Fast Track Designation for combination therapy with osimertinib for patients with EGFR mutations.

Genprex, Inc. (NASDAQ: GNPX) announced its participation in the upcoming Cell and Gene Meeting on the Mesa from October 12-16, 2020. Michael Redman, Executive VP and COO, will present on the company's innovative gene therapies targeting cancer and diabetes. The virtual event aims to tackle commercialization challenges in the cell and gene therapy sector, featuring on-demand presentations and live panels. Genprex's lead candidate, GPX-001, is in development for non-small cell lung cancer and received FDA's Fast Track Designation.

Genprex (NASDAQ:GNPX) announced its upcoming presentation at the LD 500 Virtual Investor Conference on September 1, 2020, at 1:20 p.m. ET. CEO Rodney Varner will discuss the company's product pipeline, highlighting GPX-001, which has received Fast Track Designation from the FDA for late-stage lung cancer treatment. The presentation will be available via live webcast on the conference and company websites. Genprex focuses on gene therapy advancements for cancer and diabetes, aiming to provide new treatment options.